John Maraganore, Ph.D., Joins the bluebird bio Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, a world leader in the development of innovative gene therapies for severe genetic disorders, today announced that John Maraganore, Ph.D., has joined the company’s board of directors. Dr. Maraganore has more than 25 years of experience in research and development and is the chief executive officer of Alnylam Pharmaceuticals, a leader in RNAi therapeutics.